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In this issue of Intensive Care Medicine, the steering
committee members of the PROWESS-Shock trial pres-
ent a balanced discussion of the controversies surrounding
recombinant human activated protein C (rhAPC) and the
challenges intrinsic to designing an industry-sponsored
trial [1]. The investigators have taken important steps
to be transparent about financial conflicts of interest, to
safeguard data monitoring and to ensure the validity of
statistical analysis. The purpose of the upcoming
PROWESS-Shock Trial is to prospectively test rhAPC in
a high-risk septic population—those patients with vaso-
pressor-dependent shock for C4 h. The need for this trial,
years after the regulatory approval of rhAPC for a similar
indication, is a cautionary tale that contains important
lessons for health care providers who manage patients
with sepsis, the pharmaceutical industry and the Food and
Drug Administration (FDA).
The following is an excerpt from a letter written to
Dr. Jay P. Siegel, Director of the Office of Therapeutics
Research and Review, FDA, on 22 October 2001 by four
of the ten dissenting members of the FDA advisory panel
that considered the safety and efficacy of rhAPC
(Personal communication, Suffredini A for the authors,
Cross AE, Munford R, Suffredini A, Warren S):
‘‘Despite many attempts over the last two decades,
no drug in this field [sepsis] has reproducibly
improved mortality. All agents have failed when
tested in a second confirmatory trial. Accordingly, a
drug [rhAPC] that we know to be toxic should not be
released without confirming that it does, in fact,
prolong lives…’’
After 7 years of use and two additional randomized
controlled trials (RCTs) we have finally returned to
addressing the fundamental clinical concern voiced in this
communication.
Since its approval in 2001, there has been mounting
evidence that the incidence of serious bleeding, includ-
ing cerebral hemorrhage with rhAPC is higher in clinical
practice than estimated from the original PROWESS
trial [2–4]. Because of this and the continued contro-
versy about efficacy and how to select patients who may
benefit, rhAPC has been under-utilized in the subpopu-
lation of patients for whom it was approved [5]. As the
PROWESS-Shock investigators and steering committee
members note in this issue of Intensive Care Medicine,
the results of this trial will hopefully resolve a disturbing
paradox surrounding this therapy: the PROWESS-Shock
trial may on the one hand prove that rhAPC increases
the risk of serious bleeding without providing an overall
survival benefit, or it may show that rhAPC is a safe,
life-saving therapy which has been denied to patients
due to scientific uncertainty. In either case, since the
introduction of rhAPC in 2001, some septic patients
have been adversely affected by the inadequacy of
available evidence to appropriately guide its use in
clinical practice.
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In hindsight, it may seem surprising that the FDA did not
heed the advice of the dissenting members of the advisory
committee and require a second RCT prior to approving
rhAPC. In defense of the FDA, sepsis is lethal syndrome-
affecting patients of all ages and new approaches to
improve outcome have been eagerly sought for the past
30 years. This has led to a sense of urgency and promising
results from initial trials of new therapeutic approaches
have repeatedly inflated expectations among healthcare
providers. However, the history of rhAPC clearly shows the
downside of approving drugs for sepsis based on a single
RCT. In the case of rhAPC, the risks of severe hemorrhage
and approval for a target population that was not prospec-
tively defined further compounded the lack of confirmatory
evidence demonstrating reproducibility.
In an effort to determine the importance of reproduc-
ibility in this field, we performed a MEDLINE search for
therapies used for sepsis that have undergone more than
one RCT of which at least one showed a significant
improvement in survival. Including rhAPC, we found
seven such agents: high dose corticosteroids, two anti-
endotoxin therapies, human recombinant interleukin-1
receptor antagonist (IL-1ra), intensive insulin therapy
(IIT) and intravenous immunoglobulin [4, 6–37]. Like
rhAPC, some of the agents received initial regulatory
approval or in the case of already available drugs were
widely adopted into clinical practice for the management
of severe sepsis. Of note, we chose not to discuss intra-
venous immunoglobulin as prior meta-analyses of these
studies have yielded controversial and conflicting con-
clusions beyond the scope of this editorial [34–37].
High dose corticosteroids: 1963–1989
In late 1976 and in contrast to an abstract published
earlier that same year [29], a single center, single author
RCT which enrolled 172 consecutive patients over
8 years demonstrated a 28-day mortality benefit in septic
shock with short courses of high dose corticosteroid
therapy (38 vs. 10%) [27]. While aspects of this trial
should have given clinicians pause and led to the design
of confirmatory studies, there were no appropriately
powered RCTs of high-dose corticosteroids in septic
shock for the next 7 years. Meanwhile, this therapeutic
approach was widely incorporated into the care of patients
with septic shock in many intensive care units including
our own at the National Institutes of Health (NIH) Clin-
ical Center [38]. Beginning in 1984, however, five
successive RCTs failed to show a mortality benefit from
this approach, even though several different treatment
regimens were investigated in various patient populations
with septic shock [6, 15, 22, 23, 28]. Meta-analysis of
these studies showed that high dose corticosteroid
treatment actually increased mortality in septic shock and
that the single, early trial showing benefit was in fact a
statistical outlier (Fig. 1) [39].
Anti-endotoxin antibody therapy: 1982–1992
The first generation of anti-endotoxin therapies included
plasma obtained from volunteers immunized against J5-E.
coli endotoxin or intravenous immunoglobulin prepara-
tions derived from donors selected for high titers of anti-
endotoxin antibody [7, 8, 10, 17, 25, 33]. The first RCT
testing plasma from J5-immunized subjects in patients
with gram-negative sepsis was published in 1982 and
showed significantly improved survival [33]. The accom-
panying editorial concluded that this study had ‘‘…greatly
enhanced our ability to treat successfully a large number of
very sick patients [40].’’ Despite the positive result of this
initial study and the expectations it raised, five subsequent
RCTs using either J5 antiserum or immunoglobulin
preparations containing high titers of anti-endotoxin anti-
bodies failed to demonstrate a mortality benefit [7, 8, 10,
17, 25]. Meta-analysis of these 5 RCTs (841 patients) not
only showed that J5 antiserum and polyclonal anti-endo-
toxin antibodies were not beneficial in patients with gram-
negative sepsis, but that the original published trial was a
statistical outlier (Fig. 1) [41].
Monoclonal antibody preparations including murine
(E5) and human (HA-1A) IgM preparations represented
the second generation of anti-endotoxin therapies. After a
single RCT demonstrated a survival benefit in patients
with culture proven gram-negative sepsis, HA-1A was
approved for use in Europe and parts of Asia [32]. Despite
the initial unanimous vote by its own advisory committee
in favor of approval, serious concerns about HA-1A [42],
in combination with results of a large animal sepsis model
showing harm [43], led the FDA to call for a second
clinical trial of HA-1A before granting licensure. This
subsequent trial was terminated early because of excess
mortality among HA-1A treated patients without gram-
negative bacteremia (41 vs. 37% mortality rate among
placebo treated patients) [24]. Consequently, HA-1A was
never approved for use in the US and shortly thereafter,
the manufacturer removed HA-1A from markets world-
wide. Although not harmful, E5 was also not beneficial in
two RCTs (Fig. 1) [14, 20].
IL-1 receptor antagonist, a mediator specific
anti-inflammatory agent: 1994–1997
IL-1ra is an anti-inflammatory cytokine that inhibits IL-1
signaling and its potentially harmful inflammatory effects.
1956
A human recombinant preparation of IL-1ra was tested in
three clinical trials beginning in 1994. The initial ran-
domized but unblinded phase 2 trial (n = 99) of IL-1ra
showed a dose-dependent significant survival benefit [19].
Unfortunately, this beneficial result was not reproduced
in two subsequent large RCTs (n = 1,589 combined)
(Fig. 1) [18, 26].
Intensive insulin therapy: 2001 to present
In 2001, IIT (maintaining blood glucose between 80 and
110 mg/dL) was reported to significantly improve sur-
vival in critically ill surgical patients [31]. Based on this
single center, unblinded RCT, IIT was quickly embraced
and introduced into the care of a wide range of critically
ill patients in the United States including those with
sepsis. Although not conducted in septic patients, this trial
was the primary evidence that supported the inclusion of
insulin-based glucose control in sepsis guidelines and
management bundles [44]. However, two subsequent
RCTs of IIT, including one, which specifically tested IIT
in severe sepsis, failed to demonstrate a survival benefit
while finding a 16–18% increase in severe hypoglycemia
[16, 30]. In septic patients, this severe hypoglycemia was
associated with a significantly increased incidence of
serious adverse events [16].
rhAPC: 2001 to present
In the original PROWESS study, severely septic patients
experienced an overall reduction in mortality with rhAPC
therapy (30.8 vs. 24.7%; P = 0.005) [13]. However, a
retrospective analysis by the FDA suggested that the benefit
was limited to patients with a high risk of death. Based on
this post hoc analysis, the FDA approved rhAPC only for
patients with APACHE II scores C25 or other indicators of
high mortality [45]. Similarly, the European Medicine
Agency approved rhAPC only for patients with severe
sepsis and multiorgan failure. As discussed in this issue of
Intensive Care Medicine by the authors of the PROWESS-
Shock Steering Committee, two follow-up controlled trials
involving children (RESOLVE) and adults with sepsis and
a low risk of death (ADDRESS) were both stopped early for
futility as it was highly unlikely that rhAPC would be
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Fig. 1 Each panel represents one of six therapies. The relative
risk of death (RR) is shown for each randomized controlled trial
(RCT) by a closed circle and the horizontal lines represent the 95
percent confidence interval. Significantly beneficial RCTs
(P \ 0.05) are denoted by an asterisk. In each panel, all RCTs
except the initial significantly beneficial trial are included in the
summary statistic (shown as a diamond). A test for heterogeneity
(I2) of these RCTs is shown in the upper right hand corner of each
panel. For each therapy, RCTs performed, excluding the beneficial
trial, were either overall harmful or showed no effect. When
examined across the 6 interventions, there was a significant shift in
the RR from the early beneficial trial to the final one showing no
effect (P = 0.003). ref reference, Il-1 Interleukin-1, rhAPC
recombinant human activated protein C
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superior to placebo [4, 9]. Together, these two trials
enrolled 3,039 patients and, both showed an increased risk
of serious bleeding with rhAPC compared to controls (2.4
vs. 1.0% and 2.4 vs. 1.2%; P = 0.02 for both comparisons)
that exceeded the risk of bleeding in the original
PROWESS trial [46]. In addition, patients with APACHE II
scores C25 (n = 324) or two or more organ failures
(n = 872) showed no benefit from rhAPC in the
ADDRESS trial, raising concerns about efficacy and
whether these criteria identified a population of septic
patients who were likely to benefit from the drug [47].
Conclusions
In an effort to streamline the process of approving med-
ical therapies without compromising safety, the US
Congress passed The FDA Modernization Act of 1997
[48]. Included in this document was a clarification of the
number of required clinical investigations needed for
approval:
‘‘If the Secretary determines, based on relevant
science, that data from one adequate and well-con-
trolled clinical investigation and confirmatory
evidence…are sufficient to establish effectiveness,
the Secretary may consider such data and evidence
to constitute substantial evidence for purposes of
[approval].’’
However, in the case of sepsis therapies, the history of
this field argues that two beneficial RTCs are necessary
with at least one being a confirmatory trial for the regu-
latory approval of any new drug. Confirmatory trials are
particularly germane if new therapies have life-threaten-
ing risks and inconsistent benefits across subpopulations
of patients. For the six sepsis therapies reviewed here, an
early beneficial trial was later eclipsed by subsequent
trials that were either unable to confirm efficacy or ulti-
mately demonstrated harm; this shift in treatment effect
was statistically significant across the six interventions
(P = 0.003) (Fig. 1). Four of the therapies (high dose
corticosteroids, HA-1A, rhAPC, and IIT) received either
broad clinical acceptance, governmental licensure or both.
Based on a subsequent trial, one of these therapies, HA-
1A, was removed from the markets worldwide after it was
shown to be harmful. Another, high dose corticosteroids,
was shown in later trials to have risks that outweighed any
potential benefit in septic shock and use was abandoned.
IIT has been shown in a study of septic patients to have no
benefit and to increase the risk of severe hypoglycemia.
A recent meta-analysis including trials employing more
liberal blood glucose goals (\150 mg/dL) than IIT also
found no survival benefit and an increased risk of hypo-
glycemia in critically ill patients [49]. We await the
results of the PROWESS-Shock trial in high-risk patients
to help guide future care. However, this will not change
the paradox described above that patients were potentially
harmed because a high risk and controversial therapy was
approved for sepsis without a confirmatory trial.
This pattern of inconsistent findings between trials
serves to remind us of the limits of the single RCT.
Namely, while the RCT design minimizes selection bias
within a trial, it is still only a single experiment. More-
over, performing one or more RCTs does not guarantee
the internal or external validity of the results [50]. In
sepsis research, patient population heterogeneity, high
background mortality rates, and an incomplete under-
standing of the pathogenesis have made progress slow and
costly. As such, reproducible and highly consistent evi-
dence of benefit in a clearly defined and easily identifiable
group of septic patients is essential before conferring
regulatory approval or changing clinical practice—pri-
mum non nocere.
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